- 全部删除
- 您的购物车当前为空
RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effectiveness against an EGFR-driven cancer xenograft model. The mechanism behind its efficacy can be attributed to the simultaneous inhibition of PI3K-AKT and RAS-ERK signaling pathways.
为众多的药物研发团队赋能,
让新药发现更简单!
RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effectiveness against an EGFR-driven cancer xenograft model. The mechanism behind its efficacy can be attributed to the simultaneous inhibition of PI3K-AKT and RAS-ERK signaling pathways.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 178 | 现货 | |
2 mg | ¥ 256 | 现货 | |
5 mg | ¥ 413 | 现货 | |
10 mg | ¥ 696 | 现货 | |
25 mg | ¥ 1,480 | 现货 | |
50 mg | ¥ 2,380 | 现货 | |
100 mg | ¥ 3,700 | 现货 | |
500 mg | ¥ 7,380 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 473 | 现货 |
产品描述 | RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effectiveness against an EGFR-driven cancer xenograft model. The mechanism behind its efficacy can be attributed to the simultaneous inhibition of PI3K-AKT and RAS-ERK signaling pathways. |
靶点活性 | EGFR: |
体外活性 | H1650肺腺癌细胞增殖在RTC-5 (0-40 μM; 48小时)作用下受到抑制(GI50为12.6μM)。RTC-5 (20-40 μM; 24小时)通过降低磷酸化AKT和磷酸化ERK的表达,负向调节PI3K-AKT和RAS-ERK信号通路[1]。 |
别名 | TRC-382 |
分子量 | 510.96 |
分子式 | C24H22ClF3N2O3S |
CAS No. | 1423077-49-9 |
Smiles | FC(F)(F)Oc1ccc(cc1)S(=O)(=O)NCCCN1c2ccccc2CCc2ccc(Cl)cc12 |
密度 | 1.357 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (97.86 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容